M18-03: Prophylactic cranial irradiation in patients with locally advanced non-small cell lung cancer  by Arriagada, Rodrigo & Le Pechoux, Cecile
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS204
or S. Given that SRS is minimally invasive, is able to treat lesions in 
surgically inaccessible locations, and is potentially more cost-effective 
than surgery, it is reasonable and more attractive alternative to surgery 
in the management of single brain metastasis. 
Prognostic variables in patients with brain metastases include KPS, 
number of brain metastases, and absence or presence of extra-cranial 
disease. Absence of extra-cranial disease, KPS > 70, and single (rather 
than multiple) metastasis in the brain usually predict longer survival. 
Patients who fulﬁll all these criteria will survive longer following SRS 
and will most likely beneﬁt from the increased local control achieved 
by SRS. Survival in patients who do not meet any of these criteria is 
very poor in survival, and these patients are less likely beneﬁt from 
SRS and should be treated with WBI alone. The Pros and Cons of each 
modality will be discussed at the conference.
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In most common solid tumours, such as lung and breast cancer, the 
brain is at a high risk of metastatic dissemination. Until now, small cell 
lung cancer (SCLC) has been the most studied clinical entity in this 
matter. Previously overlooked, we know now that the brain is the most 
common site of dissemination for this disease, reaching a metastasis 
rate of more than 50% at 2 years. In the early 1970’s, prophylactic 
cranial irradiation (PCI) was proposed to be included in the treatment 
strategy for SCLC and since then several randomised trials were con-
ducted [1] to evaluate this treatment. Until recent years, it was thought 
that PCI was only effective in decreasing the brain metastasis rate, but 
without a signiﬁcant effect on overall survival. This issue has been 
clariﬁed since the publication of the PCI overview [1] that analysed 
all randomised trials conducted in patients with SCLC in complete 
remission (CR). It is tempting to extrapolate this effect to other tumour 
sites with a high risk of brain metastases. However, SCLC is a unique 
tumour because of its extreme chemo and radiosensitivity. The other 
important issue to take into consideration is the potential toxic effect on 
the normal brain parenchyma. Even if it has been demonstrated that to-
tal radiation doses in the range of 24 to 30 Gy given with a fraction size 
of 3 Gy or less are not deleterious up to 3-4 years [2-3], only limited 
experience is available with a longer follow-up [4].
The rationale to propose a PCI in high risk patients is similar to that es-
tablished for SCLC patients, i.e., the brain, as a natural sanctuary to the 
drug action is a common ﬁrst site of failure, most brain metastases are 
symptomatic with a signiﬁcant impact on quality of life, and preventive 
treatment might have an impact on overall survival.
The main issues to be addressed regarding PCI in NSCLC include 
which patients are at a high risk of developing brain metastases, 
whether NSCLC cells are much less chemo or radiosensitive, which 
dose should be reached to have a therapeutic effect, if any, and which 
doses are compatible with an acceptable long-term brain function.
Risk of brain metastases in NSCLC patients
The brain metastasis risk depends on the initial stage and varies from 
5% to 15% from stage I to III [5]. Like SCLC, brain metastases ap-
pear within the ﬁrst two years of follow-up. In 75 patients with stage 
III, Stuschke et al. [6] described 20-30% of brain metastases as ﬁrst 
site of failure. Ceresoli et al. described a similar rate (22%) in locally 
advanced NSCLC [7]. However, even this higher rate would be about 
a half of that described for patients with SCLC who were complete 
responders. Thus, if it were not possible to better deﬁne a higher risk 
population, about 80% of patients would receive a useless and poten-
tially harmful treatment.
Effect of current treatment schedules in the incidence of brain metastases 
With a larger use of mostly cisplatin-based chemotherapy in locally 
advanced lung cancer a decrease of distant metastases has been shown. 
However, it seems that chemotherapy is much less effective on brain 
metastases than on other involved sites. A relative increase of brain 
metastases could be related to recent improvements of local control 
and distant metastasis rate in locally advanced NSCLC. Improved 
results have been obtained by the use of higher radiation dose with 
conformal radiotherapy, concurrent radio-chemotherapy, accelerated 
hyperfractionated radiotherapy such as CHART, and cisplatin-based 
chemotherapy. 
Effect of PCI in high risk NSCLC patients
This treatment modality has been examined in some retrospective stud-
ies and in phase III trials. 
The ﬁrst randomised trial [8] conducted by the Veterans Administration 
Lung Group included also SCLC patients, but suggested some effect 
in NSCLC. Another large study conducted by SWOG included 232 
patients [9] and showed a preventing effect by the use of 30 Gy/10-15 
fractions, but it has not been fully published. This effect was partially 
conﬁrmed in other smaller trials [10, 11]. The four trials were sum-
marised [12] and the odds ratios were estimated. In the absence of 
heterogeneity of results, these values were added to obtain a total odds 
ratio of 0.31 highly signiﬁcant (p value less than 0.0001).
Brain toxicity of PCI
Potential brain toxicity of PCI has been widely described for SCLC 
patients, mainly in retrospective series. Indeed, the two randomised 
trials which evaluated prospectively potential toxicity [2, 3] did not 
show a signiﬁcant effect of PCI up to three years of follow-up. Long-
term evaluations are eagerly needed for these materials to reach more 
deﬁnite conclusions. These two trials used generally total doses of 24 to 
36 Gy, and dose per fraction of 3 Gy or less.
Dose-effect relationship
Again, the data is coming from randomised material in SCLC patients. 
The PCI overview [1] suggested an effect of total PCI doses in sub-
group analyses, this hypothesis has been tested by an international ran-
domised trial PCI-01 that compared a total dose of 25 Gy with 36 Gy, 
the trial completed recruitment and ﬁrst results are awaited for 2008.
In summary, PCI at moderate radiation doses is an effective treat-
ment in reducing brain metastasis rate for patients at high risk of brain 
failure. This fact has been clearly demonstrated in SCLC patients in 
complete remission. Even if PCI in patients with advanced NSCLC has 
been used restrictively in clinical practice, almost 800 of such patients 
have been included in randomised trials testing the value of preven-
tive irradiation. Despite the fact that NSCLC is generally considered 
more radioresistant than SCLC, the PCI effect in terms of the propor-
tional reduction in the incidence of brain metastases is similar to that 
observed in SCLC patients. The available evidence clearly shows that 
PCI signiﬁcantly decreases the risk of brain metastases in high-risk 
patients, even using moderate total doses of approximately 30 Gy. The 
next question is whether PCI in high-risk NSCLC patients would be 
able to improve overall survival. Because of the lower risk of brain me-
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tastasis, it would be probably necessary to perform a randomised study 
including at least more than 1,000 patients. From several trial projects, 
some in Europe, only the RTOG-Intergroup US randomized trial has 
been launched and is including high risk NSCLC patients. The planned 
recruitment is above 1,000 patients and might answer the question of a 
potential effect on overall survival.
In conclusion, the controversy on the role of PCI on overall survival in 
high-risk NSCLC patients will persist in the absence of large ran-
domised studies addressing the issue. The difﬁculties to launch trials 
on this important question, which does not receive industrial ﬁnancing 
supports, are a matter of major concern. However, previous success-
ful experience of PCI in patients with SCLC certainly should encour-
age clinicians worldwide to include patients in these new randomised 
trials evaluating a potential worthwhile treatment for locally advanced 
NSCLC disease. 
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Central nervous system (CNS) failure in patients with locally advanced 
non-small cell lung cancer (LA-NSCLC) is a common and debilitating 
problem. The incidence is between 13 and 54 %.1-15,27,41 (Table 1) 
Review of RTOG data and other combined modality series have shown 
that chemotherapy signiﬁcantly decreases extra-cranial failures but 
does not decrease the risk of CNS failures. As survival lengthens the 
risk of CNS metastases increases.17-19 Studies reporting the highest 
incidence of CNS metastases include patients treated aggressively with 
multimodality therapy who have a relatively long median survival. 
(Table 1) As treatment improves for NSCLC and survival lengthens 
CNS failures will increase. 
Table 1:  Incidence of CNS metastases
CNS Metastases Median 
Survival 
(Months)
Study Stage Overall 1st Failure Site
Choi30 T1-3pN2 NA 30% 25
Stuschke3 T1-4pN2 54% 30% 20
Albain2 pN2-3 or T4 21% 15% 15
Andre12 cN2 22% 15% NA
Law10 IIIa-b or IV 31% 
(53% complete 
resection)
16.3% 
(28% complete 
resection)
20
Ceresoli11 IIb,IIIa-b NA 22% 21
Gaspar21 IIIa-b 17% 13% NA
Carolan14 III 35% 18% NA
Mamon15 IIIa 40% 34% 21
Chen41 III (preop 
therapy pCR)
55% 43% 43
There is not a standard of care for addressing CNS micro-metastases 
after successful therapy for LA-NSCLC. Most clinicians will perform 
routine physical examination with imaging of the CNS only upon 
development of signs or symptoms of CNS failure. The National 
Comprehensive Cancer Network (NCCN) guidelines for follow up of 
lung cancer include physical exam, chest x-ray, and thoracic CT scans 
at regularly deﬁned intervals. CT or MRI screening for CNS metastases 
is not included. While some investigators have evaluated and endorse 
routine neuropsychological assessment and CT or MRI screening 
for early detection of brain metastases,10,16,41 others have included 
prophylactic cranial irradiation (PCI) as part of multimodality therapy 
regimens2-4,8,22 or have suggested the need for further investigation 
of PCI.3,9,12-15,17,20 
Prospective and retrospective trials have shown that prophylactic 
cranial irradiation decreases the incidence or delays the onset of CNS 
failures in LA-NSCLC (Tables 2&3).2-7,9,22,23 Studies have not been 
powered to show a survival advantage nor have they evaluated the 
potential improvement in quality of life (QOL) or neurologic function 
by decreasing or delaying CNS metastases.
Neuropsychological complication rates of PCI in published data for 
small cell lung cancer (SCLC) and NSCLC are acceptable but data are 
limited .3,24,25 It is not known whether the beneﬁts of PCI outweigh 
the risks. Approximately 50 % of carefully selected patients with 
NSCLC treated with PCI will be treated unnecessarily. Of those treated, 
up to 13% will still have CNS failures. Early detection of asymptomatic 
CNS metastases followed by intervention with aggressive therapy may 
improve quality of life and survival without the potential risks of PCI. 
Brain metastases are more likely to be amenable to aggressive therapy 
with radiosurgery or surgical resection if disease is detected early, when 
tumor burden is low.
